Dark

OVID
Ovid Therapeutics Inc. Common Stock
stock NASDAQ

Market Open

Aug 11, 2026 2:21:17 PM EDT

2.59USD-1.336%(-0.03)539,356

2.58Bid 2.59Ask 0.01Spread

Pre-market

Aug 10, 2026 8:49:30 AM EDT

2.56USD-2.662%(-0.07)0

After-hours

Aug 10, 2026 4:44:30 PM EDT

2.54USD-3.053%(-0.08)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 3, 2022

07:26AM EST Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact Benzinga

06:36AM EST Ovid Therapeutics Pays AstraZeneca $5M Cash and 7.5M Shares of Stock for a Library of Early-Stage Small Molecules Targeting the KCC2 Transporter Benzinga

06:30AM EST Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 GlobeNewswire Inc

Dec 27, 2021

09:55AM EST 5 Value Stocks In The Healthcare Sector Benzinga

Dec 9, 2021

09:37PM EST Ovid Therapeutics Receives Notice Of Allowance For U.S. Patent Titled 'USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS' Benzinga

Nov 10, 2021

08:38AM EST Ovid Therapeutics Q3 EPS $(0.17) Up From $(0.28) YoY Benzinga

08:30AM EST Ovid Therapeutics Reports Third Quarter 2021 Business Update, GlobeNewswire Inc

Oct 7, 2021

08:30AM EDT Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors. GlobeNewswire Inc

Sep 28, 2021

10:46AM EDT Ovid Therapeutics Granted U.S. Patent Titled 'Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome' Benzinga

Sep 13, 2021

10:27AM EDT A Look Into Healthcare Sector Value Stocks Benzinga

Sep 7, 2021

08:00AM EDT Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual GlobeNewswire Inc

Aug 25, 2021

11:12AM EDT Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $4 Benzinga

Aug 24, 2021

10:42AM EDT Ovid Therapeutics Granted U.S. Patent Titled 'Methods of treating developmental disorders with gaboxadol' Benzinga

Aug 17, 2021

03:37PM EDT Ovid Therapeutics Granted Patent 'Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering' Benzinga

Aug 16, 2021

08:16AM EDT Ovid Therapeutics Q2 EPS $(0.23) Up From $(0.41) YoY Benzinga

08:00AM EDT -- Company ends Q2 21 with cash and cash equivalents of $212.2 million -- Recent appointments to Company leadership strongly position Ovid to advance current and future neuroscience programs -- Ovid is actively pursuing business development opportunities to complement its neuroscience pipeline GlobeNewswire Inc

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

04:32PM EDT Ovid Therapeutics Strengthens Board & Leadership Team to Focus GlobeNewswire Inc

Jul 7, 2021

08:00AM EDT Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at the Ladenburg Thalmann 2021 Healthcare Conference on Wednesday, July 14, 2021 at 9:30 a.m. ET. GlobeNewswire Inc

Jun 4, 2021

08:00AM EDT Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer Benzinga

08:00AM EDT Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that current Chief Business Officer Jeffrey Rona has expanded his role to include Chief Financial Officer responsibilities. GlobeNewswire Inc

May 26, 2021

08:00AM EDT -- New appointments strengthen neuroscience-focused Scientific Advisory Board GlobeNewswire Inc

May 24, 2021

09:50AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

May 13, 2021

04:18PM EDT Ovid Therapeutics Q1 EPS $2.25 Up From $(0.37) YoY, Sales $208.40M Benzinga

04:05PM EDT Ovid Therapeutics Reports First Quarter 2021 Financial Results and GlobeNewswire Inc

May 12, 2021

08:00AM EDT Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET. GlobeNewswire Inc

Apr 20, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021 Benzinga

09:11AM EDT Cantor Fitzgerald Downgrades Ovid Therapeutics to Neutral, Lowers Price Target to $4 Benzinga

08:00AM EDT Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board. GlobeNewswire Inc

Apr 19, 2021

09:16AM EDT Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions Benzinga

08:06AM EDT Ovid Therapeutics Reiterates Anticipated Quarterly Operating Expenses Guidance To Be $8M-$10M Benzinga

08:00AM EDT Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVIDs Pipeline, Including OV882 for Angelman Syndrome GlobeNewswire Inc

Apr 8, 2021

09:50AM EDT Ovid Therapeutics Granted U.S. Patent Titled 'Methods and compositions for use treating Fragile X syndrome, Angelman syndrome' Benzinga

Mar 30, 2021

08:14AM EDT Ovid Therapeutics Announces Closing Of Agreement With Takeda For Global Development, Commercialization Of Soticlestat Benzinga

08:00AM EDT Ovid Therapeutics Announces Closing of Agreement with Takeda for GlobeNewswire Inc

Mar 15, 2021

08:25AM EDT Ovid Therapeutics Q4 EPS $(0.34) Up From $(0.35) YoY, Sales $5.70M Benzinga

08:00AM EDT -- Announced signing of transaction transferring Ovids 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing GlobeNewswire Inc

Mar 9, 2021

01:21PM EST EcoR1 Capital Reports In 13G Filing A 9.6% Stake In Ovid Therapeutics Benzinga

Mar 3, 2021

10:01AM EST Stock Alert: Ovid Therapeutics Shares Surge 43% RTTNews

09:37AM EST Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes Benzinga

07:46AM EST The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study Benzinga

07:06AM EST Takeda Gets Global Rights At Closing From Ovid For Soticlestat For Dravet Syndrome, Lennox-Gastaut Syndrome RTTNews

07:02AM EST Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome Benzinga

Dec 16, 2020

07:01AM EST Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index Benzinga

07:01AM EST Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020. GlobeNewswire Inc

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

Dec 2, 2020

02:31PM EST Mid-Afternoon Market Update: Dow Edges Higher; Sequential Brands Shares Spike Higher Benzinga

02:27PM EST Mid-Day Market Update: Crude Oil Rises 3%; Ovid Therapeutics Shares Plummet Benzinga

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

05:53AM EST JMP Securities Downgrades Ovid Therapeutics to Market Perform Benzinga

Dec 1, 2020

04:54PM EST Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial Of OV101 For Treatment Of Angelman Syndrome Did Not Meet Primary Endpoint Benzinga

04:52PM EST -- OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDA -- Pivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome expected to begin in the First Half of 2021 GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 23, 2020

04:02PM EST Ovid Therapeutics Reports Will Present 2 Presentations At American Epilepsy Society Virtual Congress Dec. 4-8 Benzinga

04:01PM EST Ovid Therapeutics to Present at the American Epilepsy Society GlobeNewswire Inc

Nov 12, 2020

04:18PM EST Ovid Therapeutics Q3 EPS $(0.28) Up From $(0.43) YoY Benzinga

Oct 27, 2020

06:17AM EDT Ovid Therapeutics Granted U.S. Patent 10,813,899 "Use of Gaboxadol in the treatment of diabetes and related conditions" Benzinga

Oct 14, 2020

07:04AM EDT Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program Benzinga

07:00AM EDT Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome GlobeNewswire Inc

Oct 12, 2020

07:00AM EDT -- Four abstracts from the OV101 (gaboxadol) clinical development program in Angelman Syndrome and Fragile X Syndrome to be presented GlobeNewswire Inc

Oct 5, 2020

05:30AM EDT Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that Jeremy Levin, DPhil, MB BChir (Dr Levin) will be appointed to the Companys Board of Directors, effective October 12, 2020. GlobeNewswire Inc

Sep 30, 2020

08:12AM EDT Ovid Therapeutics Announces Soticlestat (OV935/TAK-935) Results From ARCADE And ENDYMION Studies Benzinga

08:00AM EDT -- Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time GlobeNewswire Inc

Sep 11, 2020

08:00AM EDT Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020, at 2:00 p.m. ET. GlobeNewswire Inc

Aug 26, 2020

07:32AM EDT Citigroup Maintains Buy on Ovid Therapeutics, Raises Price Target to $10 Benzinga

Aug 25, 2020

02:32PM EDT Ovid Therapeutics Move Higher; Hearing RBC Raises Price Target To $17 Benzinga

10:16AM EDT Ovid Therapeutics shares are trading higher after the company, and Takeda Pharmaceutical, announced the Phase 2 ELEKTRA study of Soticlestat met its primary endpoint, reducing seizure frequency in children with Dravet Syndrome or Lennox-Gastaut Syndrome. Benzinga

08:01AM EDT Japanese drug maker Takeda Pharmaceutical Co. Limited (TAK) and biopharmaceutical company Ovid Therapeutics Inc. (OVID) said that the randomized Phase 2 ELEKTRA study of Soticlestat in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) met the primary endpoint of reducing seizure frequency in the children. RTTNews

07:52AM EDT Ovid Therapeutics Inc. Prices 6.25M Share Common Stock Offering At $8/Share Benzinga

07:50AM EDT Ovid Therapeutics Announces Pricing of $50 Million Offering of GlobeNewswire Inc

07:08AM EDT Takeda Pharmaceutical and Ovid Therapeutics Announces Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Benzinga

07:06AM EDT Takeda Pharma: Phase 2 ELEKTRA Study Of Soticlestat Meets Primary Endpoint RTTNews

07:00AM EDT Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Business Wire

07:00AM EDT Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary GlobeNewswire Inc

Aug 10, 2020

08:11AM EDT Ovid Therapeutics Q2 EPS $(0.41) Misses $(0.36) Estimate Benzinga

08:00AM EDT Ovid Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire Inc

Aug 5, 2020

09:00AM EDT Ovid Therapeutics to Participate at the William Blair Biotech GlobeNewswire Inc

Jul 23, 2020

07:10AM EDT Ovid Therapeutics Reports Strategic Research Collaboration With University Of Connecticut For Development Of Genetic Therapy For Angelman Syndrome Benzinga

07:00AM EDT -- Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome GlobeNewswire Inc

Jul 13, 2020

10:38AM EDT Shares of Ovid Therapeutics Inc. (OVID) are climbing more than 6% Monday morning after the company said it has entered into an agreement with an Italian family-owned drug company, Angelini Pharma S.p.A. to manufacture and commercialize Ovid's OV101. RTTNews

09:04AM EDT Ovid And Angelini To Develop, Manufacture And Commercialize OV101 For Treatment Of Angelman Syndrome In Europe RTTNews

09:02AM EDT Ovid Therapeutics, Angelini Pharma Enter Into Exclusive License Agreement To Develop, Manufacture, Commercialized OV101 For Treatment Of Angelman Syndrome In Europe; Co. To Receive $20M Up Front, $212.5M Upon Achievement Of Manufacturing, Sales Milestone Benzinga

09:01AM EDT Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe PR Newswire

07:06AM EDT Ovid Therapeutics, Angelini Pharma Enter Exclusive License Agreement To Develop OV101 RTTNews

07:01AM EDT Ovid Therapeutics And Angelini Pharma Enter Into Exclusive License Agreement To Develop, Manufacture And Commercialize OV101 For The Treatment Of Angelman Syndrome In Europe; Ovid To Receive $20M Up Front And Up To $212.5M In Milestones Benzinga

07:00AM EDT Ovid Therapeutics and Angelini Pharma Enter into Exclusive License GlobeNewswire Inc